Generic Name and Formulations:
Amifostine 500mg/vial; pwd for IV infusion after reconstitution.
Indications for ETHYOL:
To reduce cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer. To reduce xerostomia in patients undergoing post-op radiation therapy for head and neck cancer where the radiation port includes a substantial portion of the parotid glands.
Pretreat with antiemetics. Reduction of renal toxicity: 910mg/m2 by IV infusion over 15 minutes once daily, starting 30 minutes before chemotherapy; monitor BP every 5 minutes during infusion and thereafter, interrupt infusion if systolic BP decreases significantly; if BP returns to normal after 5 minutes, may restart; if full dose cannot be given, then give dose of 740mg/m2 for subsequent cycles. Xerostomia: 200mg/m2 by IV infusion over 3 minutes once daily, starting 15–30 minutes before standard fraction radiation therapy; monitor BP before and immediately after infusion.
Do not use for other malignancies in which chemotherapy can produce a significant survival benefit or in patients receiving definitive radiotherapy (except in a clinical trial). Not recommended for hypotensive or dehydrated patients. Stop BP medication 24 hours before therapy when using as a chemoprotectant (do not give to patients unable to stop antihypertensives). Monitor prior to, during and after therapy; discontinue if severe cutaneous reactions, mucosal lesions, or allergic reactions occur. Ensure adequate hydration. Keep patient in supine position. Hypocalcemia risk (eg, nephrotic syndrome, multiple doses of Ethyol); monitor serum calcium. Cardiovascular or cerebrovascular disease (ischemic heart disease, arrhythmias, CHF, stroke or TIA). Elderly. Pregnancy. Nursing mothers: not recommended.
Caution with drugs that can cause hypotension.
Hypotension, hypersensitivity, nausea, vomiting, flushing, chills, malaise, fever, rash, dizziness, somnolence, hiccups, sneezing, diplopia, blurred vision, inj site reactions; rarely: severe skin reactions (eg, erythema multiforme, SJS, TEN, DRESS), reversible loss of consciousness, hypocalcemia, respiratory and cardiac arrest, renal failure, arrythmias, hypertension, seizures, syncope.
Sign Up for Free e-newsletters
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Age Not a Deterrent to Immunotherapy for Malignant Melanoma
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|